EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DIAPH3 predicts survival of patients with MGMT-methylated glioblastoma

Georges Chehade, Nady El Hajj, Mohamed Aittaleb, Maisa I Alkailani, Yosra Bejaoui, Asma Mahdi, Arwa A H Aldaalis, Michael Verbiest, Julie Lelotte, Nuria Ruiz-Reig, Irene Durá, Christian Raftopoulos und 2 weitere

Frontiers in Oncology · 22.02.2024 · 14

DOI: 10.3389/fonc.2024.1359652 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 22.02.2024. Verfasst von Georges Chehade und 13 weiteren Autor:innen. Beteiligte Einrichtung: Université Catholique de Louvain, Institute of Neuroscience, Cellular and Molecular Division, Brussels, Belgium. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation contre le Cancer, Fonds De La Recherche Scientifique - FNRS, Hamad Bin Khalifa University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma is one of the most aggressive primary brain tumors, with a poor outcome despite multimodal treatment. Methylation of the MGMT promoter, which predicts the response to temozolomide, is a well-established prognostic marker for glioblastoma. However, a difference in survival can still be detected within the MGMT methylated group, with some patients exhibiting a shorter survival than others, emphasizing the need for additional predictive factors.

Methods

We analyzed DIAPH3 expression in glioblastoma samples from the cancer genome atlas (TCGA). We also retrospectively analyzed one hundred seventeen histological glioblastomas from patients operated on at Saint-Luc University Hospital between May 2013 and August 2019. We analyzed the DIAPH3 expression, explored the relationship between mRNA levels and Patient’s survival after the surgical resection. Finally, we assessed the methylation pattern of the DIAPH3 promoter using a targeted deep bisulfite sequencing approach.

Results

We found that 36% and 1% of the TCGA glioblastoma samples exhibit copy number alterations and mutations in DIAPH3 , respectively. We scrutinized the expression of DIAPH3 at single cell level and detected an overlap with MKI67 expression in glioblastoma proliferating cells, including neural progenitor-like, oligodendrocyte progenitor-like and astrocyte-like states. We quantitatively analyzed DIAPH3 expression in our cohort and uncovered a positive correlation between DIAPH3 mRNA level and patient’s survival. The effect of DIAPH3 was prominent in MGMT -methylated glioblastoma. Finally, we report that the expression of DIAPH3 is at least partially regulated by the methylation of three CpG sites in the promoter region.

Conclusion

We propose that combining the DIAPH3 expression with MGMT methylation could offer a better prediction of survival and more adapted postsurgical treatment for patients with MGMT -methylated glioblastoma.

Schlagwörter

Stichwörter der Autor:innen

MGMT methylationO(6)-methylguanine-DNA methyltransferaseThe Cancer Genome Atlasdiaphanous forminglioblastomamDia2survival

Autor:innen und Institutionen

  • Université Catholique de Louvain, Institute of Neuroscience, Cellular and Molecular Division, Brussels, Belgium.
  • College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar.
  • Laboratory of Population Genomics, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands.
  • Department of Neuropathology, Saint-Luc University Hospital, Brussels, Belgium.
  • Department of Neurosurgery, Saint-Luc University Hospital, Brussels, Belgium.

Förderung

  • Fondation contre le Cancer
  • Fonds De La Recherche Scientifique - FNRS
  • Hamad Bin Khalifa University
  • Qatar National Research Fund

Zitieren

APA

Chehade, G., El Hajj, N., Aittaleb, M., Alkailani, M. I., Bejaoui, Y., Mahdi, A., Aldaalis, A. A. H., Verbiest, M., Lelotte, J., Ruiz-Reig, N., Durá, I., Raftopoulos, C., Tajeddine, N., & Tissir, F. (2024). DIAPH3 predicts survival of patients with MGMT-methylated glioblastoma. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1359652

Vancouver

Chehade G, El Hajj N, Aittaleb M, Alkailani MI, Bejaoui Y, Mahdi A, et al. DIAPH3 predicts survival of patients with MGMT-methylated glioblastoma. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1359652

BibTeX
@article{Chehade2024,
  author = {Chehade, Georges and El Hajj, Nady and Aittaleb, Mohamed and Alkailani, Maisa I and Bejaoui, Yosra and Mahdi, Asma and Aldaalis, Arwa A H and Verbiest, Michael and Lelotte, Julie and Ruiz-Reig, Nuria and Durá, Irene and Raftopoulos, Christian and Tajeddine, Nicolas and Tissir, Fadel},
  title = {DIAPH3 predicts survival of patients with MGMT-methylated glioblastoma},
  journal = {Frontiers in Oncology},
  year = {2024},
  volume = {14},
  doi = {10.3389/fonc.2024.1359652}
}
Kostenlos starten →